- トップ
- 研究業績
- Ogawa S, Sakamoto T, Matsuoka R, Ishitsuka K, Ogino Y, Sootome A, Makishima K, Yoshida C, Ito Y, Shimizu S, Suyama T, Shinagawa A, Ito T, Obara N, Kusakabe M, Sakata-Yanagimoto M, Miyazaki Y, Nannya Y, Chiba S. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine. Cancer Rep (Hoboken) (doi: 10.1002/cnr2.1938.) Online ahead of print Nov 28, 2023
Ogawa S, Sakamoto T, Matsuoka R, Ishitsuka K, Ogino Y, Sootome A, Makishima K, Yoshida C, Ito Y, Shimizu S, Suyama T, Shinagawa A, Ito T, Obara N, Kusakabe M, Sakata-Yanagimoto M, Miyazaki Y, Nannya Y, Chiba S. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine. Cancer Rep (Hoboken) (doi: 10.1002/cnr2.1938.) Online ahead of print Nov 28, 2023
2023/12/11
- 研究業績
- Ogawa S, Sakamoto T, Matsuoka R, Ishitsuka K, Ogino Y, Sootome A, Makishima K, Yoshida C, Ito Y, Shimizu S, Suyama T, Shinagawa A, Ito T, Obara N, Kusakabe M, Sakata-Yanagimoto M, Miyazaki Y, Nannya Y, Chiba S. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine. Cancer Rep (Hoboken) (doi: 10.1002/cnr2.1938.) Online ahead of print Nov 28, 2023
« Abe Y. Follicular lymphoma microenvironment: insights provided b... | Suma S, Suehara Y, Fujisawa M, Abe Y, Hattori K, Makishima K, Sakamot... »
